ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. - Wikidata - wikimedia - TriplyDB

ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.

ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.

http://www.wikidata.org/entity/Q34756239

about

Clinical significance of ERCC1, RRM1 and TS in non-small cell lung cancer Progress of Postoperative Adjuvant Chemotherapy in Stage I Non-small Cell Lung Cancer Prognostic value of microRNA expression in operable non-small cell lung cancer patients Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer.A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701).Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival A method for biomarker directed survival prediction in advanced non-small-cell lung cancer patients treated with Carboplatin-based therapy.Parameters for individualizing systemic therapy in non-small cell lung cancer The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures Cancer proteomics: developments in technology, clinical use and commercialization.Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC.Prognostic and predictive markers for personalized adjuvant therapy for non-small-cell lung cancer patients.Prognostic and predictive biomarkers post curative intent therapy.ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis.Response to gemcitabine-platinum chemotherapy by single nucleotide polymorphisms of RRM1 and ERCC1 genes in patients with non-small-cell lung cancer.Improving lung cancer prognosis assessment by incorporating synthetic minority oversampling technique and score fusion method.[Advance of postoperative adjuvant therapy in non-small cell lung cancer].

P2860

Q26830488-DEFA34DE-5C5C-4B85-9CDC-14C7CA3F8360 Q28080636-5571755F-120D-418F-BA7D-953E5AC3F9A5 Q28396343-F5691330-6779-4D1B-A4DA-EC5C221EFBAB Q30358684-C77FA22E-23C0-43D4-9A90-BEAC100A4E30 Q30580553-A57A1819-CAD4-4652-B9F2-40D124DB591B Q33577838-C4DCBF18-0701-4C43-8FDF-862D22E0D83F Q34074425-D593E533-DCB2-46A2-9209-2A9AE37FA34B Q34205171-5D604A60-6DE3-40CB-8819-B25497DDB8D4 Q36333164-AC0815FC-D415-4416-B873-68DF90FF4CA2 Q36926560-B97DA4FE-58BE-441C-A22A-81940EE4330E Q36951721-646CE86A-3228-4649-9B55-AE642CF3E3DC Q37225452-09D21083-6CB1-4E47-A823-3351CF7B6EE8 Q37384203-A576F885-AA81-4C0A-8F9B-4FE17FCA5078 Q37398845-BD948B0B-FC3B-427F-BC36-864CA43F8F94 Q37983690-E527F989-D37C-4081-B380-AB870AB7C6F4 Q38390072-1D7BE5F0-B3EA-4C81-A64D-B26A08E0B8F0 Q38543009-B5F8E099-302B-4831-9CE2-772435181FB3 Q38575758-8BB85292-E863-4104-8EFB-FED72BA6386A Q39303306-BE74F404-6487-4A8C-AD60-B0E49BDCC2E0 Q43026297-E206A7B5-C88C-4026-BFF9-8BDD0D4F8373 Q43680067-27801C55-13B5-4EE7-AFC0-F3C03C922541 Q47896358-96541821-0A5F-469D-8BF2-93FF085F677F Q51299691-BF3FE4F9-F7DE-4531-ADEF-43D6F8C3407A Q55464374-5D67A1E5-B815-4F65-B48C-6D4D1DD50EA0

P2860

ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.

http://www.wikidata.org/entity/Q34756239

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

ERCC1 and RRM1 in the internat ...... quantitative in situ analysis.

@ast

ERCC1 and RRM1 in the internat ...... quantitative in situ analysis.

@en

ERCC1 and RRM1 in the internat ...... quantitative in situ analysis.

@nl

type

label

ERCC1 and RRM1 in the internat ...... quantitative in situ analysis.

@ast

ERCC1 and RRM1 in the internat ...... quantitative in situ analysis.

@en

ERCC1 and RRM1 in the internat ...... quantitative in situ analysis.

@nl

prefLabel

ERCC1 and RRM1 in the internat ...... quantitative in situ analysis.

@ast

ERCC1 and RRM1 in the internat ...... quantitative in situ analysis.

@en

ERCC1 and RRM1 in the internat ...... quantitative in situ analysis.

@nl

P1433

Q34756239-5DF3BD66-06BB-464F-BF25-60E1C3755CD2

P1476

Q34756239-0E347E4B-B754-45AC-9F88-8FA852D5E7B9

P2093

Q34756239-19C50DF6-2A38-4F98-B42A-AAA57DC22EEB

Q34756239-1CA41C81-3037-4D05-9137-17C214E9251C

Q34756239-4EC4FBA6-6CFE-42E3-838E-8C9BF32C5AC0

Q34756239-4EFB0C4D-F871-47AE-BBB8-CF982868CA9E

Q34756239-65F699D6-77CA-4467-B336-150E0188BB88

Q34756239-75BC96AA-8FDA-4E0A-8307-32EF0E8F4C8D

Q34756239-90CE1B15-D296-4AA4-86DA-82A0D075F826

Q34756239-E377594C-AE13-4D88-B60A-7976A7A55CCB

Q34756239-EF94AD27-EA97-446E-8F30-C10F349D916D

Q34756239-F1B26693-B21B-47B2-A05B-742129921C7B

P2860

Q34756239-01FE1696-6E4E-4267-81F7-C538099E4F6B

Q34756239-081C70C2-B27E-4C2D-8FBA-FCF1299369CA

Q34756239-0F400EF4-DF0D-404F-A0D6-08C42E1603ED

Q34756239-1A516B31-3D74-435F-AAFA-9A4AFAED9B1D

Q34756239-2476A7C4-EDAB-4364-B03F-CD66DC0287AB

Q34756239-30A40371-9FA9-4389-BF80-D2B02E01EDBE

Q34756239-33B8AA3F-2E49-45FC-9686-CF6794D3F1D5

Q34756239-39A1844E-28C9-4DEF-B455-59610FF70623

Q34756239-40F05C09-7685-4638-9706-ED8D610E9944

Q34756239-4344B5C0-577D-4C4D-B19D-0FC088071324

P304

Q34756239-2375B849-9D68-40F8-A62D-E8BD5EEAA093

P31

Q34756239-623DFA89-5229-4E44-ACBA-356DD25D9D34

P356

Q34756239-5E184495-B584-4DAA-BD82-7C02FD6861AC

P407

Q34756239-BEC0FB69-51CE-4B43-A724-F5CD2D75B547

P433

Q34756239-F5F5410B-3D4F-4BDA-95D1-6C1081026479

P478

Q34756239-2B9D9168-B5DF-4888-B720-472654E5B789

P50

Q34756239-0ACFB1EE-61A2-4952-A645-E4D4CB602636

Q34756239-9C15B9B8-F283-4B2D-9974-12A27429A1BC

P577

Q34756239-DAA30B44-A92C-4E6B-BF6B-89CC47F97230

P5875

Q34756239-AE1ECEF8-7E56-4F1B-BC2C-2C0D29546DA3

P698

Q34756239-2D024CB3-6959-494B-8FE7-5E0075E10777

P921

Q34756239-597B4A00-3A0A-4473-A364-965C2F0C6A20

P932

Q34756239-7501E160-D6D3-430B-8218-6E1476E6A0E7

P356

J.AJPATH.2010.11.029

P1433

The American Journal of Pathology

P1476

ERCC1 and RRM1 in the internat ...... quantitative in situ analysis.

@en

P2093

Anne-Lise Vataire

http://www.w3.org/2001/XMLSchema#string

Ariane Dunant

http://www.w3.org/2001/XMLSchema#string

Gerold Bepler

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Pignon

http://www.w3.org/2001/XMLSchema#string

Ken André Olaussen

http://www.w3.org/2001/XMLSchema#string

Martin Filipits

http://www.w3.org/2001/XMLSchema#string

Michael J Schell

http://www.w3.org/2001/XMLSchema#string

Pierre Fouret

http://www.w3.org/2001/XMLSchema#string

Robert Pirker

http://www.w3.org/2001/XMLSchema#string

Zhong Zheng

http://www.w3.org/2001/XMLSchema#string

P2860

BRCA1: a novel prognostic factor in resected non-small-cell lung cancer

Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways.

RRM1-induced metastasis suppression through PTEN-regulated pathways.

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Ribonucleotide reductases in the twenty-first century.

In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.

The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments.

Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer

Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.

P304

69-78

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AJPATH.2010.11.029

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

178

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Charles Soria

Elisabeth Brambilla

P577

2010-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49744887

http://www.w3.org/2001/XMLSchema#string

P698

21224045

http://www.w3.org/2001/XMLSchema#string

P921

P932

3069904

http://www.w3.org/2001/XMLSchema#string